Aim: To investigate the pharmacodynamic and pharmacokinetic parameters of pegylated liposomal doxorubicin (PLD) combined with cyclophosphamide, vincristine, and prednisolone in patients with peripheral T-cell lymphomas (PTCL). Methods: Seven chemonaive patients and four patients with relapsed peripheral T-cell lymphomas were treated with a CCOP regimen consisting of an intravenous administration of cyclophosphamide (750 mg/m 2 ), vincristine (1.4 mg/m 2 ), and PLD (30 mg/m 2 ) on d 1, as well as an oral administration of prednisolone (60 mg/m 2 ) on d 1-5. This regimen was repeated every 3 weeks for six cycles, and the clinical response and toxicity of the regimen were monitored. In addition, the plasma concentration of PLD at different time points was determined before and after treatment. The pharmacokinetics (PKs) software was used to estimate the pharmacokinetic parameters of PLD. Results: The 11 PTCL patients received 35 treatment cycles. Three of them achieved complete response (CR), two partial response (PR), four stable disease (SD), and two progressive disease (PD). The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%. In the 7 chemonaive patients, three achieved CR, two PR, one SD, and one PD. The ORR was 71.4%, and CR rate was 42.9%. The median follow-up time was 15 months, but 6 out of 11 patients were dead at the time of data analysis. The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36). The main toxicity was myelosuppression. Oral mucositis and hand-foot syndrome seldom occurred. The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg·L -1 after administration of the CCOP regimen (0-168 h). The pharmacokinetic parameters AUC 0-∞ , CL, t 1/2 , and V d were 910.76 mg/L·h, 0.043 L·h -1 ·m -2 , 68.40 h, and 3.56 L/m 2 , respectively. Conclusion: The CCOP regimen was effective and well tolerated in patients with peripheral T-cell lymphomas. The results of the pharmacokinetic parameters showed that PLD had long retention time in blood circulation.
Introduction
Peripheral T-cell lymphomas (PTCL) are a group of rare and heterogeneous non-Hodgkin lymphoma (NHL), which have a poor prognosis and low survival rate [1] . The 5-year overall survival (OS) for common subtypes of PTCL, such as PTCL not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma, is 32% compared with only 14% for adult T-cell leukemia lymphoma [2] , and there is no standard treatment regimen at present. High-dose therapy and autologous stemcell transplants are still controversial [3, 4] . The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) remains the most commonly used chemotherapeutic treatment for PTCL. However, CHOP has poor efficacy, a low CR rate (10%-60%) and a median overall survival (OS) of <3 years [5] [6] [7] . Moreover, doxorubicin has a low therapeutic index and significant treatment-related toxicities, whereas pegylated liposomal doxorubicin (PLD) has a stable spatial structure and demonstrates reduced binding to plasma proteins. ComPharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas npg pared to conventional doxorubicin injection, PLD has a longer retention time in blood circulation, lower cardiotoxicity and improved targeted efficiency [8] . Recently, there have been several clinical studies on PLD-based NHL treatment that have shown it to be superior in the treatment of the elderly or patients with primarily cutaneous T-cell lymphomas (CTCL) with aggressive NHL [9] [10] [11] . However, there are few relative studies on the pharmacodynamic and pharmacokinetic characteristics of the cyclophosphamide, vincristine, PLD, and prednisolone (CCOP) regimen in PTCL patients. In this study, we aimed to investigate the efficiency and toxicities of a PLD-based CCOP regimen in PTCL patients, and to study the pharmacokinetics of PLD by determining its plasma concentrations at different time points after administration.
Materials and methods

Patient eligibility criteria
Patients were eligible for this study if they had histologically confirmed chemonaive or relapsed PTCL (except external precursor T-cell lymphomas) with at least one measurable lesion. The patients met several other eligibility criteria: (1) no current chemotherapy or radiotherapy treatment; (2) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2; (3) age between 18 and 75 years; (4) survival prediction ≥3 months; (5) acceptable hematologic parameters [white blood cell (WBC) ≥3.5×10 9 L -1 , absolute neutrophil count (ANC) ≥1.5×10 9 L -1 , hemoglobin (HB) ≥9.0 g/L, and platelets ≥100×10 9 L -1 ]; and (6) adequate hepatic and renal functions (liver: bilirubin ≤1.5 times the upper limit of normal (ULN), aspartate aminotransferase/alanine amiotransferase (AST/ALT) ≤1.5 times ULN or ≤5 times ULN if hepatic metastases were present; kidney: serum creatinine ≤1.5 times ULN or creatinine clearance ≥50 mL/min). The following groups were excluded: (1) pregnant or lactating women; (2) patients with other malignant tumors, except for carcinoma of the cervix uteri in situ and basal cell carcinoma of the skin; (3) patients with reactivated infection; and (4) patients with serious or untreated cardiac disease. The study was approved by the Ethics Committee of Zhejiang Cancer Hospital and all patients gave written informed consent.
Treatment plan
Patients received an intravenous (iv) infusion of cyclophosphamide (750 mg/m 2 ) within 10 min, vincristine (1.4 mg/ m 2 ) within 15 min, and pegylated liposomal doxorubicin (30 mg/m 2 ) within one hour on d 1. Prednisolone (100 mg) was administered orally on d 1 to d 5, and the entire regimen was repeated every 3 weeks for six cycles. Before the treatment a 5-HT 3 receptor antagonist was used to prevent vomiting. Granulocyte colony-stimulating factor (G-CSF) was not used in the first course as regular prevention, but it was used in the next course if grade 3/4 granulocytopenia and febrile neutropenia were present. Treatment was delayed if grade 3/4 hematologic toxicities, grade 2/4 mucositis or skin toxicities occurred. 
Response analysis
Chromatographic equipment and conditions
The Agilent 1100 high-performance liquid chromatography (HPLC) system was equipped with a G1311A pump, a G1314A programmable diode array detector (DAD) and a G1313A auto-injector. A Hewlett Packard (HP) 1000 computer with in-house developed software was used for on-line data acquisition and subsequent calculations. Separation was carried out using a Zorbax Elipse XDB-C18 (5 μm, 4.6 mm×150 mm, Agilent) column at 25 ºC and detected at 254 nm. The mobile phase consisted of acetonitrile and 40 mmol/L ammonium acetate buffer solution. Samples were eluted in gradient mode (Table 1) , and the flow rate was 0.8 mL/min. The injection volume was 50 μL. This method resulted in good separations ( Figure 1 ).
Preparation of stock and standard solutions
A reference stock solution of doxorubicin (940.0 mg/L) and an 
Assay procedure
The internal standard solution (100 μL) was added to drugfree human plasma (0.5 mL) and vortexed for one minute, followed by the addition of a 20% zinc sulfate methanol solution (0.6 mL). The sample was vortexed for one minute and then centrifuged at 10 000 round per minute for 10 min. The supernatant was filtered using a 0.45 μm filter and then 50 μL was injected into the liquid chromatography (LC) system. 
Calibration curve preparation
Results
Patient characteristics
Eleven patients with PTCL were enrolled in this study from February 2006 to December 2008. There were seven male and four female patients, and their median age was 36 years (range: 28-65 years). Seven patients were chemonaive, and four had relapsed (Table 2) . Eight patients had performance status (PS) 0-1 and three had PS 2; four patients were in stage I-II, seven patients were in stage III-IV, and six patients had B symptoms. The serum lactate dehydrogenase (LDH) of seven patients was elevated. Patients were evaluated using the International Prognostic Index (IPI) score: six patients were given a score of 0-1, three were given a score of 2 and two were given a score of 3. The pathological types were PTCL and NOS (six cases), nasal type of NK/T-cell lymphoma (two relapsed cases after radiotherapy), angioimmunoblastic T-cell lymphoma (one case), anaplastic large cell lymphoma (one case of ALK negative), and γ-δ cell skin lymphoma (one case).
Treatment received
A total of 35 cycles of chemotherapy was administered, with a median number of 3.2 cycles (range: 2-6 cycles). Six patients received 2 treatment cycles, one patient received 3 cycles, two One NK/T cell lymphoma patient with B symptoms switched to the second-line regimen, received radiotherapy treatment and was still disease-free after the three months follow-up.
Efficacy and survival
Efficacy and survival were evaluated. Three patients had CR, two had PR, four had SD, and two had PD. The ORR was 45.5% and the CR rate was 27.3%. For the seven chemonaive patients, three had CR, two had PR, one had SD, and one had PD; the ORR was 71.4% and the CR rate was 42.9%. For the four relapsed patients, there was no CR or PR patient, but three patients had SD and one patient had PD. The median follow-up time for the 11 patients was 15 months (ranging from 5 to 36 months); however, six were dead as of the time of data analysis. The one-year overall survival rate was 45.5%, and the median PFS (progression-free survival) and survival time were 6.5 months (95% CI 3.17-19.02) and 11.5 months (95% CI 6.65-16.36), respectively. A Kaplan-Meier curve for survival time was generated (Figure 2 ).
Toxicity analysis
The toxicity results of the 11 patients are shown in Table 3 . Generally, the toxicities were tolerable. The main toxicities were myelosuppression including anemia (grade 3/4, one case), neutropenia (grade 3/4, three cases) and thrombocytopenia (grade 3/4, one case). The other toxicities were rare, with no treatment-related deaths.
Plasma concentration analysis
Blood samples from nine patients treated with a CCOP regimen (without dose modification) were analyzed for plasma concentrations. Initially, at 0-8 h, plasma concentrations increased and peaked (8.490-9 .221 mg/L), then they slowly decreased to an average level of 1.704 mg/L at 168 h ( Figure  3 ).
Pharmacokinetic analysis
The plasma concentration-time data were processed by DAS software. Pegylated liposomal doxorubicin fits a biphasic kinetic model, and its pharmacokinetic parameters are shown in Table 4 . The pharmacokinetic characteristics of pegylated liposomal doxorubicin injection were significantly different 18.2 (n=2) Angioimmunoblastic T-cell lymphoma (%) 9.1 (n=1) Anaplastic large cell lymphoma (ALK negative) (%) 9.1 (n=1) γ-δ cell skin lymphoma (%) 9.1 (n=1)
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npg from conventional doxorubicin injection [12] (Table 5) , where the t 1/2 of pegylated liposomal doxorubicin was 68 h, which was 6.58 times longer than conventional doxorubicin injection. Moreover, the area under curve (AUC) of pegylated liposomal doxorubicin increased 260 fold when compared to conventional doxorubicin injection, and the clearance of pegylated liposomal doxorubicin was 0.29% of conventional doxorubicin injection. This result indicates that pegylated liposomal doxorubicin has a longer retention time in plasma circulation than conventional doxorubicin injection, and the lower V d (1.63%) indicates that it is localized and less distributed in other organs. These results are in agreement with the phase I/II clinical trials conducted by Hong [13, 14] . Gender did not affect the pharmacokinetic parameters of pegylated liposomal doxorubicin, and no significant difference was found in AUC 0-168 , AUC 0-∞ , CL, C max , t 1/2 , t max , or V d (P=0.199−0.684) ( Table 6 ). 
Discussion
The CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone) has been used extensively to treat patients with PTCL. However, it has resulted in poor outcomes except for cases of anaplasic large-cell-lymphoma kinase (ALK)-positive lymphoma. Moreover, doxorubicin has a low therapeutic index and can induce several adverse effects, such as myelosuppression, as well as heart and digestive system toxicities, especially heart damage caused by drug accumulation [15, 16] . To avoid doxorubicin toxicities, PLD was used in the current study and evaluated for clinical administration.
PLD is a long-circulating pegylated liposome, which is prone to target cancer cells. Therefore, it can reduce the toxicities associated with doxorubicin, especially the myelosuppression and cardiotoxicity. Owing to its stable spatial structure and encapsulated form, PLD has longer plasma circulation, lower clearance rate, higher blood concentration, and longer t 1/2 (68 h) when compared with conventional doxorubicin injection. Generally, normal tissues have an integrated capillary wall and most liposomes cannot pass through it, but the permeability of new vessels in tumor tissues is much higher. Several studies have reported that PLD has good remission and survival rates when used to treat basal T-cell lymphoma of the skin [15, 16] , which suggests that it is essential to investigate specific treatments for different subtypes of the PTCL. In this study, the ORR of the 11 patients was 45.5% and the CR rate was 27.3%; the 1-year overall survival rate was 45.5%, and the median PFS and survival time were 6.5 months (95% CI 3.17-19.02) and 11.5 months (95% CI 8.07-21.24), respectively. For the seven chemonaive patients, the ORR was 71.4% and the CR was 42.9%. The results were consistent with results previously described in detail using the CHOP regimen [15] [16] [17] [18] [19] . The grade 3/4 toxicities were myelosuppression including anemia (one case, 9.1%), neutropenia (three cases, 27.3%), and thrombocytopenia (one case, 9.1%), which were higher than other CHOP regimen reports [19, 20] . However, there was no cardiac toxicity case in this study. Dose-dependent cardiac toxicity is a main side effect of doxorubicin, especially in elderly patients where there is a high rate of pre-existing cardiac disease [21] . However, cardiac toxicity is common even in younger patients [22] . It has also been reported that PLD has low concentrations in the heart, kidney, stomach, and small intestine, which reduces the incidence of adverse effects in these organs normally induced by free doxorubicin [23] . Therefore, the CCOP regimen has a better therapeutic index than the CHOP regimen with equivalent or superior efficacy and lower toxicity. Of the four relapsed patients, three experienced a short paracmasis. Thus, other new regimens are still needed to treat these types of patients. The results of the pharmacokinetic parameters (Table 5) indicate that PLD had a long circulation time in the plasma, enhancing accumulation in tumor tissues, and demonstrating a superior therapeutic activity over free doxorubicin. There were no significant differences in pharmacokinetic parameters of PLD due to the patients' gender (Table  6) .
Although the data from this study of the pharmacokinetics and toxicity profile of the CCOP regimen are very favorable and encouraging, further investigations with more patients and randomized controlled studies in comparison to the CHOP regimen are warranted before new PTCL treatment guidelines can be proposed.
